1,572 results on '"Louis, Edouard"'
Search Results
2. Content Validity and Psychometric Evaluation of the Crohn’s Symptom Severity (CSS) Questionnaire in Patients with Moderately to Severely Active Crohn’s Disease
3. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
4. Serum proteome signatures associated with ileal and colonic ulcers in Crohn's disease
5. Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosis
6. Food additives impair gut microbiota from healthy individuals and IBD patients in a colonic in vitro fermentation model
7. Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for Futility
8. Efficacy and Safety of Ustekinumab for Chronic Pouchitis: A Prospective Open-label Multicenter Study
9. Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies
10. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure
11. Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study
12. Correlations for untargeted GC × GC-HRTOF-MS metabolomics of colorectal cancer
13. Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID
14. Adalimumab in Biologic-naïve Patients With Crohn’s Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID
15. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis
16. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
17. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility
18. Impact of upadacitinib induction and maintenance therapy on health-related quality of life, fatigue, and work productivity in patients with moderately-to-severely active Crohn’s disease
19. Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn’s Disease in the CELEST Extension Study
20. Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID
21. Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial
22. Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies
23. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
24. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial
25. Commentary to “[68 Ga]Ga-FAPI-04 PET/CT on assessing Crohn’s disease intestinal lesions” by Chen and colleagues
26. Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease.
27. A Synbiotic Combining Chitin–Glucan and Lactobacillus acidophilus NCFM Induces a Colonic Molecular Signature Soothing Intestinal Pain and Inflammation in an Animal Model of IBS.
28. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
29. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
30. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
31. Early heart rate variability changes during acute fetal inflammatory response syndrome: An experimental study in a fetal sheep model.
32. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes.
33. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long‐term Crohn’s disease control using real‐world evidence
34. RIGOROUS DONOR SELECTION FOR FMT IN ACTIVE ULCERATIVE COLITIS: KEY LESSONS FROM A RANDOMIZED CONTROLLED TRIAL HALTED FOR FUTILITY
35. Gentleman: a light-weight web-based projectional editor generator.
36. Risk of Late Postoperative Recurrence of Crohn’s Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers
37. Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease
38. Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group
39. Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn’s Disease
40. Consideration of Research Management and Diasporic Bonding between Higher Education Institutes in Trinidad and the Indian Diaspora: A Case Study Approach
41. Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn’s Disease
42. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease
43. Risk of Development of More-advanced Lesions in Patients With Inflammatory Bowel Diseases and Dysplasia
44. Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis
45. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease
46. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease
47. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn’s Disease: The OPERA II Study
48. S4 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
49. Ben Whishaw and Édouard Louis
50. Regional Patterns of Late Medieval and Early Modern European Building Activity Revealed by Felling Dates
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.